Mechanism of Activation of PKB/Akt by the Protein Phosphatase Inhibitor Calyculin A by Mercedes Pozuelo-Rubio et al.
ORIGINAL RESEARCH
Mechanism of Activation of PKB/Akt by the Protein Phosphatase
Inhibitor Calyculin A
Mercedes Pozuelo-Rubio • Nick R. Leslie •
Jane Murphy • Carol MacKintosh
Published online: 18 August 2010
 Springer Science+Business Media, LLC 2010
Abstract The protein phosphatase inhibitor calyculin A
activates PKB/Akt to *50% of the activity induced by
insulin-like growth factor 1 (IGF1) in HeLa cells promot-
ing an evident increased phosphorylation of Ser473 despite
the apparent lack of Thr308 phosphorylation of PKB.
Nevertheless, calyculin A-induced activation of PKB
seems to be dependent on basal levels of Thr308 phos-
phorylation, since a PDK1-dependent mechanism is
required for calyculin A-dependent PKB activation by
using embryonic stem cells derived from PDK1 wild-type
and knockout mice. Data shown suggest that calyculin
A-induced phosphorylation of Ser473 was largely blocked
by LY294002 and SB-203580 inhibitors, indicating
that both PI3-kinase/TORC2-dependent and SAPK2/p38-
dependent protein kinases contributed to phosphorylation
of Ser473 in calyculin A-treated cells. Additionally, our
results suggest that calyculin A blocks the IGF1-dependent
Thr308 phosphorylation and activation of PKB, likely due
to an enhanced Ser612 phosphorylation of insulin receptor
substrate 1 (IRS1), which can be inhibitory to its activation
of PI3-kinase, a requirement for PDK1-induced Thr308
phosphorylation and IGF1-dependent activation of PKB.
Our data suggest that PKB activity is most dependent on
the level of Ser473 phosphorylation rather than Thr308, but
basal levels of Thr308 phosphorylation are a requirement.
Additionally, we suggest here that calyculin A regulates
the IGF1-dependent PKB activation by controlling the
PI3-kinase-associated IRS1 Ser/Thr phosphorylation levels.
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Abbreviations
IGF1 Insulin-like growth factor 1
IRS1 Insulin receptor substrate 1
MAPKAP-K2 Mitogen-activated protein kinase-
activated protein kinase 2
PKB Protein kinase B (also known as
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PI3-kinase Phosphatidylinositide 3-kinase





AGC kinase family cAMP-dependent protein kinases A,
cGMP-dependent protein kinases G
and phospholipid-dependent protein
kinases C
mTOR Mammalian target of rapamycin
TORC2 Target of rapamycin complex 2
DNA-PK DNA-dependent protein kinase
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Introduction
Protein kinase B (PKB/Akt) mediates cellular responses to
insulin, growth factors and other stimuli, and is deregulated
in diseases, including cancer [1–5]. PKB belongs to the
AGC protein kinase subfamily and exists in three isoforms
(a, b and c; Akt1, 2 and 3) in mammals. In cells stimulated
by insulin or by the insulin-like growth factor 1 (IGF1),
PKB is activated by a multistep mechanism [5, 6]. Phos-
phoinositide 3-kinase (PI3-kinase) generates PI(3,4,5)P3 at
the plasma membrane, which recruits PKB to the plasma
membrane and induces a conformational change. PKB then
becomes phosphorylated by phosphoinositide-dependent
kinase-1 (PDK1) on a threonine residue (Thr308 in PKBa/
Thr309 in PKBb) in the activation loop of the catalytic
domain, while a distinct kinase phosphorylates Ser473 (in
PKBa) within a hydrophobic motif (HM) in the C-terminal
region. While the molecular identity of the Ser473 kina-
se(s) is still under investigation, recent evidence suggests
that a rapamycin-insensitive form of mammalian target of
rapamycin (mTOR), in a complex (termed TORC2) with
proteins including Rictor and GbL, mediates phosphory-
lation of Ser473 in response to insulin and IGF1 [7].
Several other kinases, including mitogen-activated protein
kinase-activated protein kinase 2 (MAPKAP-K2) and
DNA-dependent protein kinase (DNA-PK), can phosphory-
late Ser473 in vitro [8, 9]. MAPKAP-K2 cannot be the
insulin-responsive PDK2 however, because phosphoryla-
tion of Ser473 by MAPKAP-2 is independent of 3-phos-
phorylated inositol lipids, and the drug SB-203580
prevents activation of MAPKAP-K2 but does not block
insulin-stimulated phosphorylation of Ser473 in vivo [8].
Many experiments indicate that phosphorylation of
Thr308/309 by PDK1 is a requirement for activation of
PKB. For example, PKBa is neither activated nor phos-
phorylated on Thr308 in response to IGF1 in PDK1-/-
mouse embryonic stem (ES) cells [10].
We were therefore surprised to find that when serum-
deprived HeLa cells were treated with calyculin A or
okadaic acid, two potent inhibitors of PP1, PP2A and
related protein (serine/threonine) phosphatases, PKB
became highly phosphorylated at Ser473 and was acti-
vated, even though there appeared to be only basal levels of
Thr308 phosphorylation. Similarly, it had been reported
previously that PKB was activated by tumour necrosis
factor alpha (TNFa) in WEHI-164 cells by a mechanism
involving phosphorylation of Ser473 but not Thr308 [11],
and lithium activated PKB in neurons, apparently with no
phosphorylation of Thr308 [12]. How could these absences
of Thr308 phosphorylation be reconciled with the essential
role of PDK1-catalysed phosphorylation of Thr308 for
activation of PKB by insulin and IGF1 [13]? Here, the
conundrum of how calyculin A activates PKB was
dissected further in HeLa cells, and wild-type and
PDK1-/- knockout mouse ES cells.
Our data suggest that stoichiometric phosphorylation of
Ser473, with a phosphorylation basal of Thr308, supports
activation of PKB in calyculin A-stimulated cells. Mean-
while in IGF1-stimulated cells, calyculin A decreases the
IGF1-dependent Thr308 phosphorylation and activation of
PKB, likely by inducing Ser/Thr phosphorylation of Insulin
receptor substrate 1 (IRS1), which desensitizes the IGF1-
dependent stimulation of PKB.
Materials and Methods
Materials
Calyculin A, SB-203580, rapamycin and LY294002 were
from Calbiochem (CN Biosciences, UK), U0126 was from
Promega, IGF1 was from Life Technologies. Tissue culture
reagents and pre-poured Novex gels were from Invitrogen,
and protein G-Sepharose and activated CH-Sepharose were
from Amersham Pharmacia Biotech.
Antibodies
Antibodies that recognise p70-S6 kinase (isoform 1) and
residues 466–480 of PKBa/Akt1 (PKB total on western
blots) were described previously [13, 14]. Antibodies
against phospho-FKHRL1(FOXO3a) (pThr32) were from
Millipore. Antibodies against phospho-PKB (pSer473;
product 9271), phospho-PKB (pThr308; product 9275),
phospho-GSK-3 a/b (pSer21/9), phospho-p70-S6 kinase
(pThr412), p44/p42 MAPK (pThr202/pTyr204), phospho-
p38 MAPK (pThr180/pTyr182), phospho-IRS1 (pSer612)
and total anti-IRS1 were from Cell Signaling Technology.
Antibodies that immunoprecipitate PKBa were purified
by standard procedures in MRC Protein Phosphorylation
Unit. Antibodies that immunoprecipitate PDK1 and MAP-
KAP-K2 were previously described [15, 16]. Secondary
antibodies coupled to horseradish peroxidase were from
Promega. All antibodies were used according to manufac-
turers’ recommendations.
Cell Culture, Stimulation and Cell Lysis
HeLa cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (by
vol.) foetal bovine serum in a 5% CO2 humidified incu-
bator at 37C. PDK1?/? and PDK1-/- mouse ES cells
were generated and maintained as described [13]. Verifi-
cation of the identity of cell lines was performed [17]. The
cells were either kept in DMEM/serum until harvesting, or
transferred to serum free DMEM for 3 h (HeLa cells), or
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2 h (PDK1?/? and PDK1-/- ES cells). Where added,
calyculin A (200 nM) was included throughout the period
of serum starvation or for the equivalent time in serum-
containing medium. Where included, IGF1 (100 ng/ml)
was added to serum-starved cells for 15 min. Where indi-
cated the following inhibitors of protein kinases were added
to serum-starved cells, for an additional 60 min: LY294002
(100 lM), U0126 (10 lM), SB-203580 (10 lM). Rapa-
mycin was included for 30 min (100 nM).
Cells were extracted in lysis buffer comprising 50 mM
Tris (pH 7.5), 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton
X-100, 10 mM b-glycerophosphate, 50 mM sodium fluo-
ride, 1 mM sodium orthovanadate, 5 mM sodium pyro-
phosphate, 0.27 M sucrose, 1 mM benzamidine, 0.2 mM
PMSF, 10 lg/ml leupeptin and 0.1% (by vol.) 2-mercap-
toethanol. Lysates were centrifuged at 13,000g for 10 min
at 4C. The supernatants were snap frozen and stored at
-80C until use. Protein concentrations were determined
by the Bradford method using bovine serum albumin as
standard.
Activities of Protein Kinases that were
Immunoprecipitated from Cell Lysates
Thawed lysates (300 lg protein) were clarified by centri-
fugation and PDK1 was immunoprecipitated by an estab-
lished procedure [13]. PKB was immunoprecipitated from
lysates (200 lg protein) with 10 lg antibody coupled to
10 ll protein G-Sepharose, and PKB activity in immuno-
precipitates was assayed [14]. The activity of MAPKAP-K2
was assayed as described previously [18]. In vitro assays
of PI3-kinase broadly followed the method previously
described [19]. For all kinases, one unit was the amount
that catalysed the phosphorylation of 1 nmol substrate in
1 min.
Statistical Analysis
Independent experiments were pooled when the coefficient
of variance could be assumed identical. Statistical signifi-
cance was evaluated by using t-test Student (n = number
of experiments). P values of under 0.05 were considered
significant.
Results and Discussion
PKBa in Calyculin A-Treated Cells is Recognised
by Phosphospecific pSer473-PKBa Antibodies
Using a phospho-specific pSer473-PKBa antibody, we
found that calyculin A prevented dephosphorylation of
Ser473 of endogenous PKBa when HeLa cells were
transferred from serum-containing to serum free medium
(Fig. 1). Consistent with previous reports [20, 21], caly-
culin A by itself promoted strong phosphorylation of
Ser473 in serum free medium in the absence of other
inducers (Fig. 1). Similarly, calyculin A stimulated the
phosphorylation of p70-S6 kinase at Thr412, which lies in
a hydrophobic region and is analogous to Ser473 in PKB
[5, 22].
The Calyculin A-Induced Phosphorylation of Ser473
on PKBa is Inhibited by Both LY294002
and SB-203850
The strong phosphorylation of Ser473 of PKB could be
because calyculin A blocks a protein phosphatase that
dephosphorylates this site. However, while PP2A can
dephosphorylate pSer473 in vitro [23], other findings
Fig. 1 Calyculin A-treated HeLa cells promote an increased phos-
phorylation of Ser473 in PKBa. HeLa cells grown in serum were
treated with calyculin A (200 nM) for 3 h, or transferred to serum free
medium for 3 h while treated with or without calyculin A (200 nM).
Where indicated, cells were stimulated with IGF1 (100 ng/ml) for
15 min prior to harvesting. Protein lysates were resolved on 10%
SDS-PAGE gels, transferred to nitrocellulose membranes and probed
with indicated antibodies. This is a representative blot of similar
experiments run in duplicate. Densitometrical analysis was performed
and calculation of phospho/total ratios of the different kinases was
performed
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indicate that pSer473 is dephosphorylated by a PH-domain
containing protein phosphatase (PHLPP) belonging to
the calyculin A-insensitive PPM class of PP2C-related
enzymes [24]. It is possible that the PHLPP is indirectly
inhibited by calyculin A. In any case, the Ser473 kinase(s)
would have to be at least slightly active for calyculin A to
induce an accumulation of phosphate on this site.
To identify the kinase(s) responsible for phosphorylat-
ing Ser473 in calyculin A-treated cells, we preincubated
the cells with protein kinase inhibitors before adding
calyculin A to the cell medium. The inhibitor of PI3-
kinase/Akt/mTOR signalling, LY294002 [25], largely
inhibited the calyculin A-stimulated phosphorylation of
Ser473, consistent with the calyculin A-induced phos-
phorylation of Ser473 this being at least partially depen-
dent on the activity of a kinase downstream of PI3-kinase,
presumably target of rapamycin complex 2 (TORC2)
(Fig. 2a).
SB-203580, a specific inhibitor of SAPK2/p38a/b [26],
also partially blocked the calyculin A-induced phosphory-
lation of Ser473 (Fig. 2a). Calyculin A promoted the
phosphorylation of SAPK2/p38a/b at sites whose phos-
phorylation is required for activation, namely Thr180 and
Tyr182 (Fig. 1), and also activated MAPKAP-K2, which is
downstream of SAPK2/p38 (data not shown). These find-
ings indicate that SAPK2/p38a/b/ MAPKPAP-K2 pathway
also contributes to the calyculin A-activation of PKB,
consistent with previous reports of okadaic acid-stimulated
activation of MAPKAP-K2 [27] and that MAPKAP-K2 can
phosphorylate Ser473 of PKB in vitro [28–30].
Neither rapamycin, which targets certain forms of
mTOR [31], nor U0126, which inhibits the activation of
the mitogen-activated protein kinase (MAPK/ERK) [32],
affected Ser473 phosphorylation (Fig. 2a), though calycu-
lin A promoted phosphorylation and activation of MAPK
(Fig. 1 and data not shown). In term of comparison, IGF1-
dependent phosphorylation of PKB in the presence of these
inhibitors has been included in supplementary information
(Supplementary Fig. 1).
Calyculin A also promoted the activation of PKB in
HeLa cells, albeit to a lesser extent than IGF1 (Figs. 2b, 3).
Similar to the Ser473 phosphorylation, the calyculin
A-induced activation of PKB was partially blocked by LY
294002, and partially by SB-203580 (Fig. 2b), confirming
contributions of PI3-kinase- and SAPK2/p38-dependent
kinases. LY294002 and SB-203580 together did not com-
pletely block calyculin A-induced phosphorylation of
Ser473 (not shown) and activation of PKB (Fig. 2b),
however, indicating that a third kinase pathway might
contribute to phosphorylation of this site in calyculin
A-treated cells. In contrast, the calyculin A-induced phos-
phorylation of p70-S6 kinase on Thr412 and activation of
this enzyme were both completely blocked by LY294002
Fig. 2 SB-203580 and LY294002 partially inhibit the calyculin
A-induced PKB activation and Ser473 phosphorylation. HeLa cells
were transferred to serum free medium and where indicated treated
with IGF1 (100 ng/ml) for 15 min prior to harvesting. Additionally,
the following inhibitors of protein kinases were added for an
additional 1 h: LY294002 (100 lM), U0126 (10 mM), SB-203580
(10 lM), whereas rapamycin (100 nM) was added for 30 min.
Thereafter, calyculin A (200 nM) was added for a further 30 min,
and cells were lysed. a Protein lysates (25 lg protein) were separated
on 10% SDS-PAGE gels, transferred to nitrocellulose membranes and
probed with indicated antibodies. b The cells were lysed, and PKBa
was immunoprecipitated from the lysates and assayed. Activities are
the average ± SD (n = 3, * P = 0.004, ** P = 0.00065, *** P =
0.00067, Student t-test). c The cells were lysed, and p70-S6 kinase
was immunoprecipitated from the lysates and assayed. Activities are
the average ± SD (n = 3, * P = 0.0045, ** P = 0.0065, *** P =
0.0024, Student t-test). Densitometrical analysis was performed and
calculation of phospho/total ratios of the different kinases was
performed
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and rapamycin (Fig. 2c), and were therefore PI3-kinase/
mTOR dependent. However, SB-203580 did not block
either calyculin A-induced Thr412 phosphorylation or
activation of p70-S6 kinase indicating that these events are
independent of SAPK2/p38-dependent kinases. These data
support a previous report suggesting that zinc sulphate
activates PI3-kinase, MAPK, JNK, SAPK2/p38 and p70-S6
kinase in neurons, the stimulation of p70-S6 kinase phos-
phorylation being mainly dependent on rapamycin and
LY294002 inhibitors [33]. Some years ago, a report sug-
gested that calyculin A prevented both rapamycin- and
sorbitol-mediated deactivation of p70-S6 kinase; thus, it
was suggested that osmotic stress and rapamycin act
through a calyculin A-sensitive phosphatase to cause
dephosphorylation and deactivation of p70-S6 kinase
[34]. Additionally, other reports suggest that a calyculin
A-sensitive phosphatase is required for the rapamycin- or
amino acid deprivation-induced dephosphorylation of
p70-S6 kinase, showing a direct protein phosphatase-2A
(PP2A)/p70-S6 kinase interaction; furthermore, the inacti-
vation of p70-S6 kinase activity through a PP2A-dependent
mechanism leads to the inhibition of protein synthesis in
endothelial cells [35, 36].
Calyculin A Promotes Phosphorylation of GSK-3a,
GSK-3b and FOXO3a
Calyculin A induced phosphorylation of GSK-3a, GSK-3b
and FOXO3a on sites that are known to be phosphorylated
by PKB in response to IGF1 (Fig. 1 [37, 38]). FOXO3a ran
as an upwards smear on the western blot of the calyculin
A-treated samples, probably indicative of multiple phos-
phorylations of this protein. The ubiquitously expressed
protein GSK-3 is constitutively active; however, its activity
is markedly diminished following phosphorylation of
Ser21 of GSK3a and Ser9 of GSK3b by PKB, while
dephosphorylation events mediated by C(2)-ceramide
(N-acetyl-sphingosine)-dependent stimulation of PP2A
promotes GSK3 activation [39]. Phosphorylation of
GSK-3a, GSK-3b and FOXO3a are consistent with PKB
being active in these cells.
PKB in Calyculin A-Treated Cells was not Recognised
by pThr308-PKBa Antibodies
Despite the strong phosphorylation of Ser473 and activa-
tion of PKB that were induced by calyculin A, only a basal
level of Thr308 phosphorylation of PKB in the calyculin
A-treated HeLa cells was detected using the pThr308-
PKBa phospho-specific antibody (Figs. 1, 2b, 3). When
HeLa cells were transferred to serum free medium, stim-
ulation with calyculin A activated PKB to *50% of that
induced by IGF1, which was about the same activity as
seen when the cells were growing continuously in serum
(Fig. 3). Furthermore, PKB activity in cells treated with
both IGF1 and calyculin A was about the same as in cells
exposed to calyculin A alone, showing a marked decrease
in Thr308 phosphorylation compared with IGF1 stimula-
tion alone (Figs. 1, 3). Thus, the calyculin A-induced PKB
activation was accompanied by a strong phosphorylation of
Ser473, while calyculin A apparently blocked the IGF1-
dependent Thr308 phosphorylation (Fig. 1). Additionally,
the observation that calyculin A suppressed serum-induced
PKB activity could be explained because calyculin A may
block the Thr308 phosphorylation and PKB activation in
response to growth factors present in serum-containing
media at the same levels as calyculin A reduces the Thr308
phosphorylation and activation of PKB in response to
IGF1. Furthermore, the fact that calyculin A used in serum
free media promotes an increased PKB activation than in
serum stimulated cells is intriguing, nevertheless our feel-
ings points to a fast inactivation of the serum-dependent
Thr308 phosphorylation mediated by calyculin A. This can
be reflected by quickly promoting a decreased PKB activity
compared with that found in cell stimulated with calyculin
A in serum free medium.
Similar findings have been reported for PKB in caly-
culin A-treated 3T3-L1 cells recognised by the pSer473-
PKBa, but not by the pThr308-PKBa antibody [20, 21].
Calyculin A and okadaic acid prevented the phosphoryla-
tion of Thr308 in response to the cytokine granulocyte-
macrophage colony-stimulating factor, but did not inhibit
Fig. 3 Calyculin A promotes PKBa activation. HeLa cells grown in
serum were incubated for 3 h in the absence (Serum) or presence of
200 nM calyculin A (Serum ? Caly A). HeLa cells transferred to
serum free medium for 3 h were incubated with calyculin A (Caly A)
(200 nM for 3 h), IGF1 (IGF1) (100 ng/ml for 15 min) or both (Caly
A ? IGF1) as indicated. The cells were lysed, and PKBa was
immunoprecipitated from the lysates and assayed. Activities are the
average ± SD (n = 3, * P = 0.035, Student t-test)
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Ser473 phosphorylation [40]. However, our results are in
contrast with those of Yamada et al [41] who reported that
calyculin A prolonged the insulin-stimulated phosphory-
lation of Thr308 in Chinese hamster ovary cells.
That calyculin A-triggered activation of PKB in the
apparent basal level of Thr308 phosphorylation was puz-
zling, given that phosphorylation of Thr308 of PKB by
PDK1 has been reported many times to be mandatory for
activation of PKB [8, 10, 42].
PKBa is not Activated by Calyculin A in PDK1-/- ES
Cells
The possibility that activation of PKBa by calyculin A does
not require PDK1 and phosphorylation of Thr308 was ruled
out when we examined phosphorylation and activity of
PKB in response to calyculin A in PDK1?/? and PDK1-/-
mouse ES cells [10] (Fig. 4). As expected [10], PKB was
activated, and Thr308 and Ser473 phosphorylated in
response to IGF1 in PDK1?/? cells (Fig. 4), whereas in
PDK1-/- cells, IGF1 stimulated Ser473 phosphorylation
but failed to induce Thr308 phosphorylation or PKB acti-
vation (Fig. 4). It is interesting to mention that the total
PKB was much less in the PDK1-/- than in PDK1?/? ES
cells probably due to the lack of PDK1 which may affect in
some way the expression levels of PKB.
Similarly to HeLa cells, calyculin A promoted an active
PKB induced to*50% of that induced by IGF1 in PDK1?/?
ES cells, which was about the same activity as seen when
the cells were growing continuously in serum. According
to data obtained in HeLa cells (Fig. 3), PKB activity in
PDK1?/? ES cells treated with both IGF1 and calyculin A
was about the same as that in cells exposed to calyculin A
alone (Fig. 4), while a strong phosphorylation of Ser473 is
observed and a marked decreased of Thr308 phosphory-
lation compared with IGF1 stimulation alone. For com-
parison, note that while PKB activity in calyculin A-treated
cells was similar to that in serum-grown cells, the pThr308-
PKBa immunoreactivity of calyculin A-induced PKB was
markedly less than that extracted from serum-grown cells
(Fig. 4). These data suggest that an increased phosphory-
lation of Ser473 under basal levels of Thr308 phosphory-
lation may support similar levels of PKB activation to
those found under physiological serum-growth conditions.
Nevertheless, despite the apparent extremely low Thr308
phosphorylation, the activation of PKB by calyculin A
cannot be entirely due to the Ser473 phosphorylation,
because PDK1 is a requirement. Thus, the traces of Thr308
phosphorylation seem to be needed because no PKB
activity was seen in the calyculin A-treated PDK1-/- cells,
even showing strong Ser473 phosphorylation levels
(Fig. 4).
Calyculin A Promotes Ser612 Phosphorylation of IRS1
and Inhibits IGF1-Stimulated IRS1-Associated
PI3-kinase
When IGF1 and calyculin A were tested in combination,
the activation of PKB was no higher than that promoted by
the protein phosphatase inhibitor alone (Figs. 3, 4). Simi-
larly, Schubert et al [40] reported that okadaic acid acti-
vated PKB and prevented any additional activation in
response to cytokine granulocyte-macrophage colony-
stimulating factor in TF-1 cells. To understand why caly-
culin A blocked any further activation of PKB by IGF1, the
enzymes PDK1 and PI3-kinase in the pathway by which
IGF1 activates PKB were assayed.
PDK1 activity was found to be similar in extracts of
unstimulated cells, serum-grown cells and IGF1- and
calyculin A-treated HeLa cells (Fig. 5) consistent with
proposals that PDK1 is constitutively active, and is targeted
to PKB when both protein kinases are recruited to the
plasma membrane by 3-phosphorylated inositol lipids
generated by PI3-kinase.
Fig. 4 PKBa is not activated by calyculin A in PDK1-/- mouse ES
cells. PDK1?/? and PDK1-/- ES cells were grown in the presence of
serum (Serum). Some cells were transferred into serum free medium
for 2 h, in the absence (Serum free) or presence of 200 nM calyculin
A (Caly A), and where indicated cells were incubated for 15 min in
the presence of 100 ng/ml IGF1. The cells were lysed, and PKBa was
immunoprecipitated from the lysates and assayed. Activities are the
average ± SD (n = 3, * P = 0.03, Student t-test). In addition,
protein lysates were separated on 10% SDS-PAGE gels, transferred
to nitrocellulose membranes and probed with indicated antibodies.
Densitometrical analysis was performed and calculation of phospho/
total ratios of the different kinases was performed
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PI3-kinase is activated in cells when its regulatory
subunit binds to phosphotyrosine residues of activated
growth factor receptors or adaptor proteins, such as the
insulin receptor substrate (IRS) proteins [43–45]. A decade
ago, it was suggested that TNFa is a mediator of insulin
resistance in infection, tumour cachexia and obesity by
IRS1 phosphorylation on serine residues, and this increased
serine phosphorylation interferes with insulin-induced
tyrosine phosphorylation of IRS1 and impairs insulin
action [46]. Recently, previous works analysing the role of
serine phosphorylation of IRS1 in mediating fat-induced
insulin resistance, in mice skeletal muscle in vivo, the
mutation of IRS1 Ser612 to alanine protected from fat-
induced insulin resistance showing the important role of
Ser612 phosphorylation of IRS1 in mechanisms of insulin
resistance [47]. Thus, aimed at analysing the implication of
Ser phosphorylation of IRS1 in the process by which
calyculin A decreased the IGF1-dependent Thr308 phos-
phorylation and activation of PKB, levels of Ser612
phosphorylation were analysed in HeLa cells stimulated
with calyculin A. The results suggest that calyculin A
Fig. 5 Calyculin A does not affect extractable PDK1 activity. HeLa
cells grown in serum were incubated for 3 h in the absence (Serum) or
presence of 200 nM calyculin A (Serum ? Caly A), or were
transferred to serum free medium for 3 h and stimulated in the
absence (Serum free) or presence of calyculin A (Caly A) (200 nM for
3 h), IGF1 (IGF1) (100 ng/ml for 15 min) or both (Caly A ? IGF1).
The cells were lysed and PDK1 was immunoprecipitated from the
lysates and assayed. Activities are the average ± SD, n = 3
Fig. 6 Calyculin A increases
Ser612 phosphorylation of
IRS1. HeLa cells grown in
serum were incubated with
calyculin A (200 nM)
(Serum ? Caly A) for indicated
times (a) or during 3 h for
shown concentrations (c). HeLa
cells transferred to serum free
medium for 3 h were incubated
with calyculin A (200 nM)
(Serum free ? Caly A) for
indicated times (b) or for 3 h for
shown concentrations (d).
Protein lysates were resolved on
10% SDS-PAGE gels,
transferred to nitrocellulose
membranes and probed with
indicated antibodies.
Densitometrical analysis was
performed and calculation of
phospho/total ratios of the
different kinases was performed
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promotes phosphorylation of Ser612 of IRS1 in a dose and
time-dependent manner (Fig. 6). Furthermore, phosphory-
lation of Ser612 of IRS1 was also evident during IGF1
treatment in the presence of calyculin A (Fig. 7).
Stimulation of cells with IGF1 induced a 32-fold
increase in IRS1-associated PI3-kinase activity, which was
strongly blocked by calyculin A (Fig. 7). In addition,
calyculin A blocked the basal PI3-kinase activity associ-
ated with IRS1. These findings with calyculin A are con-
sistent with serine/threonine phosphorylation of IRS1
preventing recruitment of PI3-kinase, which has been dis-
covered in normal physiological regulation and in disease
states such as insulin resistance (reviewed in [44, 45]). For
example, okadaic acid inhibited association of IRS1 and
PI3-kinase stimulated by IGF1 in astrocytoma cells [43],
and TNFa induced seryl phosphorylation of IRS1, and this
effect was mimicked by okadaic acid and calyculin A [46].
The finding that calyculin A blocks IGF1-induced IRS1-
associated PI3-kinase activity (Fig. 7) likely dependent
on a strong Ser612 phosphorylation of IRS1, probably
explains why Thr308 phosphorylation and PKB activity
from cells treated with IGF1 plus calyculin A were not
higher than that seen with calyculin A alone (Figs. 3, 4).
Conclusion
The aim of this work was to analyse interesting observa-
tions on phosphorylation and activation PKB during stim-
ulation with phosphatase inhibitor; first, how a strong
phosphorylation of Ser473 of PKB, with apparent lack of
Thr308 phosphorylation, may support PKB activation and;
second, how calyculin A blocks the IGF1-dependent
Thr308 phosphorylation and activation of PKB.
Our data suggest that calyculin A promotes phosphory-
lation of Ser473 in PKB supporting levels of PKB activation
similar to those found under physiological conditions in
serum-growth cells, even with basal levels of Thr308
phosphorylation. These data suggest that PKB activity is
most dependent on the level of Ser473 phosphorylation
rather than Thr308 phosphorylation supporting previous
reports [48]. Nevertheless, our data with PDK1?/? and
PDK1-/- mouse ES cells suggest that a basal phosphory-
lation of Thr308 is required for calyculin A-dependent
activation of PKB. Furthermore, our data suggest that
calyculin A-induced phosphorylation of Ser473 was largely
blocked by LY294002 and SB-203580, indicating that both
PI3-kinase/TORC2-dependent and SAPK2/p38-dependent
protein kinases contributed to phosphorylation of Ser473 in
calyculin A-treated cells.
Additionally, our data suggest that Ser612 phosphory-
lation of IRS1 by calyculin A could explain why IGF1
stimulation in the presence of calyculin A did not promote
activation of PI3-kinase, phosphorylation of Thr308 and
IGF1-dependent PKB activation.
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Fig. 7 Calyculin A blocks basal and IGF1-stimulated IRS1-associ-
ated PI3-kinase. HeLa cells were transferred to serum free medium in
the absence (Serum free) or presence of calyculin A (Caly A) (200 nM
for 3 h), IGF1 (IGF1) (100 ng/ml for 15 min) or both (Caly
A ? IGF1). The cells were lysed and IRS1 and its associated
protein(s) immunoprecipiated from the lysates and assayed for
PI3-kinase activity. Activities are the average ± SD (n = 3, * P =
0.0016, Student t-test). In addition, protein lysates were separated on
10% SDS-PAGE gels, transferred to nitrocellulose membranes and
probed with indicated antibodies. Densitometrical analysis was
performed and calculation of phospho/total ratios of the different
kinases was performed
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